LY09004 is approved to enter the clinic, Luye Pharma accelerates global biopharmaceutical layout

LVYE Pharmaceutical Group announced that its biological antibody drug ly09004 has been approved by the State Drug Administration to carry out clinical trials In addition to ly09004, LVYE pharmaceutical has entered into different clinical stages at home and abroad, and its R & D is progressing smoothly As one of the business focus of future development, LVYE pharmaceutical will continue to increase investment in research and development of biopharmaceuticals, accelerate the global layout of biopharmaceuticals, and add new driving force for future performance growth
Ly09004 is a recombinant human vascular endothelial growth factor receptor antibody fusion protein ophthalmic injection It is a bioequivalent drug of eylea It is suitable for neovascular (wet) senile maculopathy, macular edema after retinal vein occlusion, diabetic macular edema and diabetic retinopathy and choroidal neovascularization secondary to pathological myopia in diabetic macular edema patients Visual impairment caused by tube Public data shows that Eylea's global sales in 2018 reached 2 billion 185 million euros LVYE pharmaceutical is very optimistic about the market demand and growth potential of this kind of drugs Nowadays, biopharmaceutical industry has become an important component and growth impetus of Chinese and even global pharmaceutical industry Public data shows that from 2016 to 2022, the global biopharmaceutical market is expected to grow from US $2020 billion to US $326 billion, with a compound annual growth rate of 8.3% The market size of domestic biopharmaceuticals is also expected to reach 326.9 billion yuan in 2021 In recent years, both macro policies and industrial environment have provided powerful opportunities for the development of biopharmaceuticals Green leaf pharmaceutical has seized the market opportunity, started the research and development of biotechnology drugs at home and abroad simultaneously, and established the development platform of biological antibody technology At present, the research and development of several biological antibody drugs at home and abroad are progressing smoothly
In addition to ly09004, the company has a number of biological antibody products in different clinical stages in China, including the recombinant anti VEGF humanized monoclonal antibody injection ly01008 (Avastin's biological analogue) which has entered the phase III clinical stage, used for the treatment of colorectal cancer or non-small cell lung cancer; the recombinant anti RANKL all human monoclonal antibody injection ly06006 (proli), which has been successfully developed in phase I clinical trial A) for the treatment of osteoporosis in postmenopausal women, and ly01011 (xgeva) for the treatment of multiple myeloma and bone metastasis caused by solid tumor
In addition, LVYE also cooperates with a number of foreign leading biopharmaceutical companies to continuously enrich and supplement the follow-up product pipeline in the field of Biopharmaceutics, including the joint development of new bispecific antibody products in the field of tumor immunology with abpro, a comprehensive life science company in the field of synthetic biology, and the joint development with Excel, an American biotechnology company, for the next generation of tumor immunity The therapeutic antibody of epidemic therapy and the development of car-t therapy in cooperation with elpis.